On February 22, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that it will present single-agent data of the IMM0306 Phase I and IMM27M Phase I clinical trials and preclinical data of  IMM5605  in the form of  poster presentations at the 2024 American Association for Cancer Research (AACR 2024) Annual Meeting hold in San Diego, USA, April 5-10.

Founder and chairman of ImmuneOnco 

Dr. Tian, Wenzhi said:

    "The AACR Annual Meeting is one of the largest international academic events in the field of cancer in the world, covering comprehensive research on the etiology and treatment of cancer. The results we presented at AACR 2024 will help inform the industry of the latest clinical data from IMM0306, IMM27M and IMM5605 preclinical studies. We are excited to have the opportunity to share these data with our oncology peers and look forward to further clinical data releases for these products."

Chief Medical Officer/Senior Vice President of ImmuneOnco 

Dr. Lu said:

    The research results of a total of three projects, IMM0306, IMM27M and IMM5605, have been recognized and affirmed by this year's AACR. IMM0306 has entered Phase II clinical trials in multiple NHL indications, including monotherapy and combination with lenalidomide. In phase I Clinical trial of IMM27M, data showed favorable clinical efficacy and good safety in tumor types including relapsed and refractory breast cancer and melanoma and RP2D was determined, We look forward to rapidly advancing the clinical development of IMM0306, IMM27M and IMM5605 products, bringing new treatment options to the treatment of cancer patients and addressing unmet clinical needs."